<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000863</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 314</org_study_id>
    <secondary_id>11289</secondary_id>
    <nct_id>NCT00000863</nct_id>
  </id_info>
  <brief_title>A Study of WR 6026 in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients</brief_title>
  <official_title>A Phase II Study of WR 6026 for Pneumocystis Carinii Pneumonia in People With HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of WR 6026 once daily in the treatment of mild PCP. To evaluate the&#xD;
      safety and tolerance of WR 6026. To assess the correlation between plasma WR 6026&#xD;
      concentrations and outcome/toxicity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will receive an initial loading dose of WR 6026, followed the next morning and&#xD;
      each morning thereafter by 1 of 2 lower doses of WR 6026 taken in a fasting state for 3&#xD;
      weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">July 1998</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>45</enrollment>
  <condition>Pneumonia, Pneumocystis Carinii</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitamaquine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Any medications not listed as excluded will be permitted on study.&#xD;
&#xD;
        [ AS PER AMENDMENT 4/11/97:PCP prophylaxis is permitted if initiated after the Day 21&#xD;
        evaluation has been completed.]&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documented HIV infection.&#xD;
&#xD;
          -  Documented PCP.&#xD;
&#xD;
          -  On a room air ABG, the PO2 value greater than or equal to 70 mm Hg and the (A-a) DO2&#xD;
             less than 35 mm Hg.&#xD;
&#xD;
          -  Signed informed consent from parent or legal guardian for those patients less than 18&#xD;
             years of age.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Known hypersensitivity to quinolines.&#xD;
&#xD;
          -  If patient is unwilling or unable to discontinue other medications with anti-PCP&#xD;
             activity during the treatment period of this study.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any patient unwilling or unable to discontinue other medications with anti-PCP&#xD;
             activity during the treatment period of this study (e.g., TMP/SMX, sulfonamides,&#xD;
             dapsone, pentamidine, trimetrexate, atovaquone, clindamycin, azithromycin,&#xD;
             pyrimethamine, primaquine).&#xD;
&#xD;
          -  Methemoglobinemia-producing agents (dapsone, primaquine, sulfonamides, chloroquine,&#xD;
             nitrofurantoin, nitrates and nitrites).&#xD;
&#xD;
        Patients with the following prior conditions or symptoms are excluded:&#xD;
&#xD;
          -  History of G6PD deficiency, hemoglobin M abnormality, or NAD methemoglobin reductase&#xD;
             deficiency.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  More than 24 hours receipt of anti-PCP treatment for the current episode of PCP.&#xD;
             Receipt of prior PCP prophylaxis is permitted, as long as it is discontinued at study&#xD;
             entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dohn M</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Petty B</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Black J</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Frame P</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Therapeutics CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Med. Ctr.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Hawaii at Manoa, Leahi Hosp.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weiss Memorial Hosp.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Infectious Disease Research Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Wishard Memorial</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hosp. of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY - Buffalo, Erie County Medical Ctr.</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Cincinnati CRS</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univ. AIDS CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Petty BG, Black JR, Hendrix CW, Lewis LD, Basiakos Y, Feinberg J, Pattison DG, Hafner R. Escalating multiple-dose safety and tolerance study of oral WR 6026 in HIV-infected subjects: AIDS clinical trials group 173. J Acquir Immune Defic Syndr. 1999 May 1;21(1):26-32. doi: 10.1097/00126334-199905010-00004.</citation>
    <PMID>10235511</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Pneumonia, Pneumocystis carinii</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>WR 6026</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

